Somatostatin Receptor Antagonists as a Theranostic Option in Iodine-Refractory Thyroid Carcinoma

J Nucl Med. 2023 Dec 1;64(12):2001. doi: 10.2967/jnumed.123.265639.

Authors

Johanna S Enke¹, Ralph A Bundschuh², Georgine Wienand², Nic G Reitsam³, Malte Kircher², Christian H Pfob², Constantin Lapa², Alexander Dierks²

Affiliations

¹ Nuclear Medicine, Faculty of Medicine, University of Augsburg, Augsburg, Germany; and johanna.enke@uk-augsburg.de.
² Nuclear Medicine, Faculty of Medicine, University of Augsburg, Augsburg, Germany; and.
³ Pathology, Faculty of Medicine, University of Augsburg, Augsburg, Germany.

PMID: 37321826
DOI: 10.2967/jnumed.123.265639

No abstract available

MeSH terms

Humans
Iodine*
Precision Medicine
Receptors, Somatostatin
Somatostatin
Thyroid Neoplasms* / diagnostic imaging
Thyroid Neoplasms* / drug therapy
Thyroid Neoplasms* / pathology

Substances

Receptors, Somatostatin
Iodine
Somatostatin